Charting the translational pathway: ISSCR best practices for the development of PSC-derived therapies

By afschroeder • January 24, 2026

Barry J, Abranches E, Baptista RP, Barry C, Brandsten C, Bruce K, Carpenter MK, Cavagnaro J, Collins L, Csaszar E, Dashnau J, de Villa D, Fynes K, Gabaldo M, Hao J, Harel-Adar T, Hei D, Henchcliffe C, Hidalgo-Simon A, Hollands J, Hursh D, Jackman S, Kelly K, Kim JH, Kim H, Kino-Oka M, Lakshmipathy U, Lamb T, Lazic SE, Loring JF, Ludwig TE, Mariappan I, Monville C, Mountford JC, Nagy A, Okano H, Pellegrini G, Persson A, Prutton K, Rasko JEJ, Sareen D, Sato Y, Shnaiderman A, Stacey G, Svendsen CN, Tomishima M, Trounson A, Viswanathan S, Wang S, Wydenbach K, Zhang A, Zylberberg C, Mosher JT, Bharti K. Charting the translational pathway: ISSCR best practices for the development of PSC-derived therapies. Stem Cell Reports. 2026 Jan 22:102784. doi: 10.1016/j.stemcr.2025.102784. Epub ahead of print. PMID: 41576937.

Tags: biomedical sciences, Cedars Sinai DoM, clinical translation, pluripotent stem cells, Publications

Related Posts

Are Urologists and/or Radiation Oncologists Biased when Reporting of Advantages and Disadvantages of Surgery versus Radiation in Consultations for Early-Stage Prostate Cancer?

Friedrich NA, Luu M, Gale R, Chaplin A, Polineni R, Shiang A, Shin D, Freedland SJ, Spiegel B, Ballas LK, Kokorowski P, Daskivich TJ. Are[...]

Diagnostic Performance of F-18 Flurpiridaz in Women: A Sub-study of the Aurora Phase 3 Trial

Horgan SJ, Heller GV, Maddahi J, Bateman TM, Bax JJ, Beanlands RSB, Berman DS, Garcia EV, Somer E, Tamaki N, Thompson D, Udelson JE. Diagnostic[...]

Comparing Clinical Outcomes of Patients With a Small Versus Large Annulus After Newer-Generation Balloon-Expandable Transcatheter Aortic Valve Replacement

Suruga K, Patel V, Nagasaka T, Guo Y, Shitan H, Ng D, Cohen T, Garg T, Ahlawat P, Koren O, Patel D, Gupta A, Chakravarty[...]